PMGC Holdings Inc. (ELAB) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. PMGC Holdings Inc. (formerly Elevai Labs Inc.) has transitioned from a skincare development company to a diversified holding company following the sale of its skincare business on January 16, 2025. The company now operates through three wholly-owned subsidiaries: Northstrive BioSciences Inc. (biopharmaceuticals), PMGC Research Inc. (medical research), and PMGC Capital LLC (investment firm). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue (Continuing Ops) | $0 | $0 |
| Net Loss (Total) | $(2,170,810) | $(2,809,741) |
| Net Loss (Continuing Ops) | $(2,160,301) | $(1,097,032) |
| Operating Expenses | $2,215,242 | $1,356,216 |
| Cash and Cash Equivalents | $5,682,628 | $3,984,453 (Dec 31, 2024) |
| Working Capital | $6,976,543 | $4,251,867 (Dec 31, 2024) |
| Accumulated Deficit | $(15,440,437) | $(13,269,627) (Dec 31, 2024) |
| Investments in Securities | $624,838 | $139,084 (Dec 31, 2024) |
Note: The company reported $0 revenue from continuing operations. Discontinued operations (skincare business) generated $152,381 in revenue for the six months ended June 30, 2025.
Material Changes vs. Prior Period
- Business Model Shift: The sale of the skincare business in January 2025 resulted in the classification of that segment as discontinued operations. The company now focuses on biotech, research, and investment holding.
- Operating Expenses: Total operating expenses increased by $859,026 (63%) compared to the prior six-month period. This was driven by a $458,647 increase in professional fees (due to restructuring and financing) and a $248,070 increase in office and administrative costs.
- Investment Activity: The company significantly expanded its investment portfolio, purchasing $995,100 in securities and receiving $1,109,921 in proceeds from sales. This resulted in a realized loss of $371,494 and an unrealized gain of $238,899.
- Intangible Assets: The company terminated a license agreement (License #1), recognizing a gain of $129,613. It also expanded License #2 into the animal health market.
- Capital Structure: The company completed two reverse stock splits (1-for-200 and 1-for-7) in late 2024 and early 2025. Shares outstanding increased from 438,987 to 1,477,575 due to equity issuances.
Guidance, Outlook, and Risks
Management Outlook: Management plans to focus on increasing revenue through PMGC Capital LLC's investment activities, advancing clinical development for Northstrive BioSciences (specifically the EL-22 asset for obesity/muscle preservation), and pursuing acquisitions of operating B2B companies with positive EBITDA.
Going Concern: The filing includes a "Going Concern" warning. Despite a strong cash position of $5.68 million, the company has an accumulated deficit of $15.4 million and incurred a net loss of $2.17 million for the six months ended June 30, 2025. Management states that continued operations depend on obtaining necessary equity financing and the attainment of profitable operations.
Risks and Contingencies:
- Capital Needs: Reliance on raising additional debt or equity financing to fund operations and acquisitions.
- Investment Volatility: Significant exposure to fair value changes in securities and convertible debentures.
- Regulatory: Risks associated with clinical trials and FDA approvals for biotech assets.
- Related Party Transactions: Significant consulting fees paid to entities controlled by the CEO and Chairman.
Subsequent Events:
- July 7, 2025: Acquired 100% of Pacific Sun Packaging Inc. for $1.148 million cash plus earn-out.
- July 18, 2025: Acquired AGA Precision Systems LLC for $650,000 cash.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $5.68M cash balance against the $2.5M operating cash burn for the six-month period.
- Revenue Generation: Confirm timelines for revenue recognition from the new subsidiaries (Northstrive, PMGC Capital) as continuing operations currently show $0 revenue.
- Investment Valuation: Review the fair value assumptions for the $624,838 investment portfolio, particularly the convertible debenture and private equity holdings.
- Related Party Fees: Scrutinize the $745,902 in consulting fees, a significant portion of which is paid to entities controlled by key management.
- Acquisition Integration: Assess the financial impact and integration plans for the two acquisitions (Pacific Sun and AGA Precision) completed in July 2025.